Skip to main content
Caplight Logo









Mesenkia Therapeutics AB

Mesenkia Therapeutics AB

Private
UppsalaHealthcare & Life Scienceshttps://mesenkia.com/

Last Round

VC Round

May 22, 2026

Total Funding Raised

$590,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Mesenkia Therapeutics AB is a biotechnology company that develops biological drug candidates for the treatment of glioblastoma.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyglioblastoma treatmentantibody therapeuticsbiologics platformdrug discoverybispecific antibodiesantibody-drug conjugatesADCblood-brain barrierBBB-enabledoncology researchmonoclonal antibodiesmAbsprecision medicinecancer immunotherapybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mesenkia Therapeutics AB Comparables

Compare Mesenkia Therapeutics AB with similar companies based on industry and business-model similarity.

Mesenkia Therapeutics AB comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Adaptin Bio
81%
Targepeutics
79%
Merck & Co., Inc.
69%

Mesenkia Therapeutics AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 22, 2026
SeedJun 2, 2025

Key People

Founding team and executive leadership

Moa Fransson

CEO

Executive Team

Mesenkia Therapeutics AB Investors

Notable investors and investment history

Mesenkia Therapeutics AB investors
InvestorRounds
Almi Invest ABSeed
Uppsala University InvestSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2026

    Grew 60% from 5 to 8 employees this quarter.

  • May 22, 2026

    Raised a VC Round with participation from lsi-zeta.

Mesenkia Therapeutics AB Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mesenkia Therapeutics AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mesenkia Therapeutics AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersUppsala
Employee Range8
Year Founded2023
Last FundingMay 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?